Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

By sjmartinez • February 19, 2025

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID: 39967197.

Tags: breast cancer, Electronic health records, Geriatric oncology, Hematology/Oncology, Outcomes, Publications, Risk factor, Treatment, women’s oncology

Related Posts

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer

Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar[...]

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]